98%
921
2 minutes
20
The global incidence of Type 2 diabetes (T2D) is on the rise, fueled by factors such as obesity, sedentary lifestyles, socio-economic factors, and ethnic backgrounds. T2D is a multifaceted condition often associated with various health complications, including adverse effects on bone health. This study aims to assess key biomarkers linked to bone health and remodeling-Osteoprotegerin (OPG), Receptor Activator of Nuclear Factor Kappa-Β Ligand (RANKL), and Glycoprotein Non-Metastatic Melanoma Protein B (GPNMB)-among individuals with diabetes while exploring the impact of ethnicity on these biomarkers. A cross-sectional analysis was conducted on a cohort of 2083 individuals from diverse ethnic backgrounds residing in Kuwait. The results indicate significantly elevated levels of these markers in individuals with T2D compared to non-diabetic counterparts, with OPG at 826.47 (405.8) pg/mL, RANKL at 9.25 (17.3) pg/mL, and GPNMB at 21.44 (7) ng/mL versus 653.75 (231.7) pg/mL, 0.21 (9.94) pg/mL, and 18.65 (5) ng/mL in non-diabetic individuals, respectively. Notably, this elevation was consistent across Arab and Asian populations, except for lower levels of RANKL observed in Arabs with T2D. Furthermore, a positive and significant correlation between OPG and GPNMB was observed regardless of ethnicity or diabetes status, with the strongest correlation (r = 0.473, < 0.001) found among Arab individuals with T2D. Similarly, a positive and significant correlation between GPNMB and RANKL was noted among Asian individuals with T2D (r = 0.401, = 0.001). Interestingly, a significant inverse correlation was detected between OPG and RANKL in non-diabetic Arab individuals. These findings highlight dysregulation in bone remodeling markers among individuals with T2D and emphasize the importance of considering ethnic variations in T2D-related complications. The performance of further studies is warranted to understand the underlying mechanisms and develop interventions based on ethnicity for personalized treatment approaches.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11117910 | PMC |
http://dx.doi.org/10.3390/biomedicines12051019 | DOI Listing |
PLoS One
September 2025
Department of Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
There is a lack of longitudinal data on type 2 diabetes (T2D) in low- and middle-income countries. We leveraged the electronic health records (EHR) system of a publicly funded academic institution to establish a retrospective cohort with longitudinal data to facilitate benchmarking, surveillance, and resource planning of a multi-ethnic T2D population in Malaysia. This cohort included 15,702 adults aged ≥ 18 years with T2D who received outpatient care (January 2002-December 2020) from Universiti Malaya Medical Centre (UMMC), Kuala Lumpur, Malaysia.
View Article and Find Full Text PDFJAMA Netw Open
September 2025
Perelman School of Medicine, University of Pennsylvania, Philadelphia.
Importance: As obesity rates rise in the US, managing associated metabolic comorbidities presents a growing burden to the health care system. While bariatric surgery has shown promise in mitigating established metabolic conditions, no large studies have quantified the risk of developing major obesity-related comorbidities after bariatric surgery.
Objective: To identify common metabolic phenotypes for patients eligible for bariatric surgery and to estimate crude and adjusted incidence rates of additional metabolic comorbidities associated with bariatric surgery compared with weight management program (WMP) alone.
Diabetes Ther
September 2025
Eli Lilly and Company, Lilly Corporate Center, 893 Delaware Street, Indianapolis, IN, 46225, USA.
Introduction: This study examines the characteristics of adults with type 2 diabetes (T2D) who were not initially treated with an antihyperglycemic agent (AHA).
Methods: The analyses used Optum de-identified Market Clarity data from January 2013 through September 2023. The US study included nonpregnant adults with T2D who were continuously insured from 1 year prior through 5 years post diagnosis and did not fill a prescription for an AHA in the year after their initial T2D diagnosis.
J Prim Care Community Health
September 2025
Division of Epidemiology and Biostatistics, School of Public Health, Faculty of Health Sciences, University of Cape Town, South Africa.
Objectives: The COVID-19 pandemic disrupted routine healthcare services, disproportionately affecting people living with chronic conditions such as type 2 diabetes (T2D). In response, the Western Cape Government Health implemented home delivery of medication (HDM) via community health workers (CHWs) to maintain continuity of care. This study aimed to evaluate the association between socioeconomic factors and access to HDM among T2D patients in Cape Town, South Africa, during the pandemic, with a focus on equity and health system responsiveness.
View Article and Find Full Text PDFBMJ Open Diabetes Res Care
September 2025
NIHR Maudsley Biomedical Research Centre, South London and Maudsley NHS Foundation Trust, London, UK.
Introduction: Frequent glycated hemoglobin A1c (HbA1c) monitoring is recommended in individuals with type 2 diabetes mellitus (T2D). We aimed to identify distinct, long-term HbA1c trajectories following a T2D diagnosis and investigate how these glycemic control trajectories were associated with health-related traits and T2D complications.
Research Design And Methods: A cohort of 12,435 unrelated individuals of European ancestry with T2D was extracted from the UK Biobank data linked to primary care records.